Cadonilimab delivered 84.6% complete responses in an earlier study. Can Akeso prove lasting benefit?
Akeso starts Phase III cadonilimab testing in colon cancer, with 386 patients planned and recurrence outcomes central to its clinical strategy.
Pharma & Biotech